Company Overview

Founded: 2019

Headquarters: Vancouver, Canada

Market Cap: $2.1M (as of Q4 2024)

Share Price: $0.025

Regulatory Status: Pre-clinical development stage

Company Link

Entheon Biomedical Corp.

Core Development Programs

Primary Research Focus

• Main Compounds: DMT derivatives (EBI-002)
• Target Conditions: Substance Use Disorders, particularly nicotine addiction
• Development Stage: Preclinical development
• Expected Milestones: Completion of preclinical studies

Clinical Pipeline

• Lead Program Status: EBI-002 in preclinical development
• Secondary Programs: Genetic testing and biomarker research
• Trial Locations: Planning phase
• Number of Patients: Preclinical stage

Technology Platform

Drug Development Approach

• Synthesis Method: Proprietary DMT derivative development
• Delivery System: Novel delivery systems under development
• Patent Status: Patents pending on compounds and delivery methods
• Unique Technology: Personalized medicine approach using genetic screening

Research Infrastructure

• Lab Facilities: Contract research organizations
• Research Partnerships: Academic institutions
• Equipment/Technology: Genetic screening technology
• Data Management: Biomarker and genetic data platform

Financial Position

Current Finances

• Cash Position: $800K
• Burn Rate: $150K monthly
• Revenue: Pre-revenue stage
• Debt: Minimal debt

Funding History

• Recent Raises: $3M financing (2023)
• Major Investors: Private investors
• Grant Funding: Research collaboration funding
• Expected Runway: Through Q2 2025

Management Team

Key Leadership

• CEO Background: Timothy Ko – Founder and CEO
• Scientific Team: Dr. Christopher Gondi (Chief Scientific Officer)
• Advisory Board: Addiction treatment specialists
• Board of Directors: Biotech and finance executives

Market Strategy

Commercial Approach

• Target Market Size: $5B+ addiction treatment market
• Pricing Strategy: Premium personalized treatment approach
• Distribution Plans: Clinical partnerships
• Partnership Strategy: Seeking strategic collaborations

Competitive Position

• Main Competitors: Traditional addiction treatment providers, other psychedelic companies
• Key Advantages: Personalized medicine approach, genetic screening
• Market Share: Pre-commercial stage
• Barriers to Entry: Novel technology platform

Risk Assessment

Development Risks

• Clinical Trial Risks: Early stage development uncertainties
• Regulatory Hurdles: Complex regulatory pathway
• Technical Risks: Novel compound development
• Timeline Risks: Development delays

Market Risks

• Competition: Increasing competition in addiction treatment
• Funding Risks: Ongoing capital requirements
• Regulatory Changes: Evolving psychedelic regulations
• Patent Protection: Early-stage IP portfolio

Investment Metrics

Key Performance Indicators

• Cash per Share: $0.01
• Institutional Ownership: 5%
• Insider Ownership: 25%
• Short Interest: 0.3%

Analyst Coverage

• Number of Analysts: 0
• Price Targets: N/A
• Consensus Rating: N/A
• Recent Changes: No current coverage

Development Timeline

Near-Term Catalysts

• Next 6 Months: Preclinical data readouts
• 12-Month Outlook: Potential IND-enabling studies
• Long-term Goals: Clinical trial initiation by 2026

Regulatory Pathway

• FDA Status: Pre-IND stage
• Other Jurisdictions: Exploring multiple jurisdictions
• Expected Approvals: 2027-2028 timeline

Standard Disclaimer

This analysis is provided for informational purposes only and does not constitute investment advice. The psychedelic medicine sector involves significant risks including, but not limited to, clinical trial failures, regulatory challenges, market volatility, and potential loss of investment. Companies in this sector are often in early development stages with no approved products or revenue. The regulatory landscape for psychedelic medicines is evolving and uncertain. Past performance does not guarantee future results. Investors should conduct their own due diligence and consult with financial and legal advisors before making any investment decisions. Market conditions and company circumstances can change rapidly. All information presented is subject to update and revision. Author(s) may have positions in securities mentioned.

Learn More About Psychedelic Medicine Investments

For a comprehensive overview of the psychedelic medicine investment landscape, including market analysis, regulatory environment, and investment strategies, read our in-depth guide: The Psychedelic Renaissance: A New Frontier in Mental Health Treatment and Investment Opportunities